Inotropes, vasopressors, and pulmonary vasodilators’ effects on haemodynamics in adult congenital heart disease patients
| Drug . | Cardiac output . | PVR . | SVR . | Tachycardia/arrhythmia . |
|---|---|---|---|---|
| Inodilators | ||||
| ȃDobutamine | ||||
| ȃ <5 mcg/kg/min | ↑ | ↘ | →/↘ | ++ |
| ȃ5–15 mcg/kg/min | ↑↑ | → | ↘ | +++ |
| ȃMilrinone | ↑↑ | → | ↘↘ | ++ |
| Inopressors | ||||
| ȃEpinephrine | ↑↑ | →/↘ | ↑↑ | +++ |
| ȃDopamine | ↑ | → | ↑↑ | +++ |
| ȃ <2 mcg/kg/min | ↑ | → | ↑ | ++ |
| ȃ5–10 mcg/kg/min | ↑↑ | → | ↑ | +++ |
| ȃ10–20 mcg/kg/min | ↑ | → | ↑↑ | ++++ |
| ȃNorepinephrine | ↑ | →/↑ | ↑↑ | + |
| Vasopressors | ||||
| ȃVasopressin | →/↑ | →/↘ | ↑↑ | — |
| ȃPhenylephrine | →/↑ | →/↑ | ↑↑ | — |
| Pulmonary vasodilators | ||||
| ȃInhaled nitric oxide | →/↑ | ↘↘ | ↘ | — |
| ȃEpoprostenol | →/↑ | ↘↘ | ↘ | — |
| Drug . | Cardiac output . | PVR . | SVR . | Tachycardia/arrhythmia . |
|---|---|---|---|---|
| Inodilators | ||||
| ȃDobutamine | ||||
| ȃ <5 mcg/kg/min | ↑ | ↘ | →/↘ | ++ |
| ȃ5–15 mcg/kg/min | ↑↑ | → | ↘ | +++ |
| ȃMilrinone | ↑↑ | → | ↘↘ | ++ |
| Inopressors | ||||
| ȃEpinephrine | ↑↑ | →/↘ | ↑↑ | +++ |
| ȃDopamine | ↑ | → | ↑↑ | +++ |
| ȃ <2 mcg/kg/min | ↑ | → | ↑ | ++ |
| ȃ5–10 mcg/kg/min | ↑↑ | → | ↑ | +++ |
| ȃ10–20 mcg/kg/min | ↑ | → | ↑↑ | ++++ |
| ȃNorepinephrine | ↑ | →/↑ | ↑↑ | + |
| Vasopressors | ||||
| ȃVasopressin | →/↑ | →/↘ | ↑↑ | — |
| ȃPhenylephrine | →/↑ | →/↑ | ↑↑ | — |
| Pulmonary vasodilators | ||||
| ȃInhaled nitric oxide | →/↑ | ↘↘ | ↘ | — |
| ȃEpoprostenol | →/↑ | ↘↘ | ↘ | — |
Modified from: Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. 2017. Circulation.
Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: a document of the Acute Cardiovascular Care Association of the European Society of Cardiology. European Heart Journal: Acute Cardiovascular Care. 2022.
Inotropes, vasopressors, and pulmonary vasodilators’ effects on haemodynamics in adult congenital heart disease patients
| Drug . | Cardiac output . | PVR . | SVR . | Tachycardia/arrhythmia . |
|---|---|---|---|---|
| Inodilators | ||||
| ȃDobutamine | ||||
| ȃ <5 mcg/kg/min | ↑ | ↘ | →/↘ | ++ |
| ȃ5–15 mcg/kg/min | ↑↑ | → | ↘ | +++ |
| ȃMilrinone | ↑↑ | → | ↘↘ | ++ |
| Inopressors | ||||
| ȃEpinephrine | ↑↑ | →/↘ | ↑↑ | +++ |
| ȃDopamine | ↑ | → | ↑↑ | +++ |
| ȃ <2 mcg/kg/min | ↑ | → | ↑ | ++ |
| ȃ5–10 mcg/kg/min | ↑↑ | → | ↑ | +++ |
| ȃ10–20 mcg/kg/min | ↑ | → | ↑↑ | ++++ |
| ȃNorepinephrine | ↑ | →/↑ | ↑↑ | + |
| Vasopressors | ||||
| ȃVasopressin | →/↑ | →/↘ | ↑↑ | — |
| ȃPhenylephrine | →/↑ | →/↑ | ↑↑ | — |
| Pulmonary vasodilators | ||||
| ȃInhaled nitric oxide | →/↑ | ↘↘ | ↘ | — |
| ȃEpoprostenol | →/↑ | ↘↘ | ↘ | — |
| Drug . | Cardiac output . | PVR . | SVR . | Tachycardia/arrhythmia . |
|---|---|---|---|---|
| Inodilators | ||||
| ȃDobutamine | ||||
| ȃ <5 mcg/kg/min | ↑ | ↘ | →/↘ | ++ |
| ȃ5–15 mcg/kg/min | ↑↑ | → | ↘ | +++ |
| ȃMilrinone | ↑↑ | → | ↘↘ | ++ |
| Inopressors | ||||
| ȃEpinephrine | ↑↑ | →/↘ | ↑↑ | +++ |
| ȃDopamine | ↑ | → | ↑↑ | +++ |
| ȃ <2 mcg/kg/min | ↑ | → | ↑ | ++ |
| ȃ5–10 mcg/kg/min | ↑↑ | → | ↑ | +++ |
| ȃ10–20 mcg/kg/min | ↑ | → | ↑↑ | ++++ |
| ȃNorepinephrine | ↑ | →/↑ | ↑↑ | + |
| Vasopressors | ||||
| ȃVasopressin | →/↑ | →/↘ | ↑↑ | — |
| ȃPhenylephrine | →/↑ | →/↑ | ↑↑ | — |
| Pulmonary vasodilators | ||||
| ȃInhaled nitric oxide | →/↑ | ↘↘ | ↘ | — |
| ȃEpoprostenol | →/↑ | ↘↘ | ↘ | — |
Modified from: Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. 2017. Circulation.
Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: a document of the Acute Cardiovascular Care Association of the European Society of Cardiology. European Heart Journal: Acute Cardiovascular Care. 2022.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
